Menu Search

Company Announcements

Latest announcements

Date and timeCompanyHeadlineSource
Trend Micro to Secure AI-Enabled Private Data Centers WorldwidePR Newswire
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placeboBusiness Wire
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerBusiness Wire
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerBusiness Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapyBusiness Wire
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine TherapyBusiness Wire
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual MeetingPR Newswire
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLCPR Newswire
CLP𝑒 Teams Up with CityUHK to Install Solar Power System Across the CampusEQS Newswire
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCOPR Newswire
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLCPR Newswire
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract CancerPR Newswire
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual MeetingPR Newswire
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual MeetingPR Newswire
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time EverGlobeNewswire
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)Business Wire
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024Business Wire
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract UpdatesPR Newswire
RNS announcements are delayed by up to an hour.
...